BenzingaAugust 14, 2026 at 8:16 AM NY2 Months Ago
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
